Unity Biotechnology Inc. (NASDAQ:UBX) and Eyenovia Inc. (NASDAQ:EYEN) compete with each other in the Biotechnology sector. We will analyze and compare their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unity Biotechnology Inc.	N/A	0.00	76.40M	-6.20	0.00
Eyenovia Inc.	N/A	0.00	17.25M	-1.43	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Unity Biotechnology Inc. and Eyenovia Inc.

Profitability

Table 2 represents Unity Biotechnology Inc. (NASDAQ:UBX) and Eyenovia Inc. (NASDAQ:EYEN)’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Unity Biotechnology Inc.	0.00%	0%	0%
Eyenovia Inc.	0.00%	-70.4%	-66.2%

Liquidity

The current Quick Ratio of Unity Biotechnology Inc. is 15.4 while its Current Ratio is 15.4. Meanwhile, Eyenovia Inc. has a Current Ratio of 12.3 while its Quick Ratio is 12.3. Unity Biotechnology Inc. is better positioned to pay off its short-term and long-term debts than Eyenovia Inc.

Analyst Recommendations

Unity Biotechnology Inc. and Eyenovia Inc. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Unity Biotechnology Inc.	0	0	1	3.00
Eyenovia Inc.	0	0	0	0.00

The upside potential is 167.52% for Unity Biotechnology Inc. with average target price of $21.

Institutional and Insider Ownership

Institutional investors held 37.6% of Unity Biotechnology Inc. shares and 10% of Eyenovia Inc. shares. Unity Biotechnology Inc.’s share held by insiders are 0.2%. Competitively, insiders own roughly 2.1% of Eyenovia Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Unity Biotechnology Inc.	4.13%	-9.62%	-13.18%	-40.91%	0%	-36.41%
Eyenovia Inc.	2%	45.71%	54.55%	0.79%	-44.5%	78.95%

For the past year Unity Biotechnology Inc. had bearish trend while Eyenovia Inc. had bullish trend.

Summary

Unity Biotechnology Inc. beats on 4 of the 7 factors Eyenovia Inc.

Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.